Literature DB >> 21749297

Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif.

Marion Jurk1, Ghania Chikh, Bettina Schulte, Andrea Kritzler, Denise Richardt-Pargmann, Catherine Lampron, Rachel Luu, Arthur M Krieg, Alain P Vicari, Jörg Vollmer.   

Abstract

Microbial infections trigger a multiplicity of responses in the host via innate immune sensors, including the Toll-like receptors (TLRs). TLR7 and TLR8, located in endosomes, detect pathogen-derived RNA, which can be mimicked by synthetic single-stranded oligoribonucleotides (ORNs). Detailed analysis of the immunostimulatory properties of numerous silencing RNAs (siRNAs) revealed that almost all tested siRNAs with a phosphodiester backbone actively stimulated cytokine production in human peripheral blood immune cells, but not all of them did contain previously described guanosine/uridine TLR7 or adenosine/uridine TLR8 motifs. By analysis of sequence variants of these siRNAs (as single- or double-strands), we were able to identify a new immunostimulatory, non-uridine-rich TLR7 motif that is present in many published siRNAs. Interestingly, the activity of this motif is dependent on the backbone chemistry. Phosphorothioate ORNs containing the motif did not stimulate immune activation, whereas phosphodiester ORNs of the same sequence induced a strong TLR7-biased immune response with high amounts of interferon-alpha. Using TLR7- and Myd88-deficient mice, we demonstrated that stimulation by ORNs containing this motif was TLR7 dependent. Our findings are of therapeutic relevance as this motif is present in many siRNA sequences and will to contribute to the immunostimulatory properties of unmodified siRNAs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21749297     DOI: 10.1089/nat.2011.0298

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  10 in total

1.  Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands.

Authors:  Nathaniel M Green; Krishna-Sulayman Moody; Michelle Debatis; Ann Marshak-Rothstein
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

Review 2.  Therapeutic targeting of microRNAs: current status and future challenges.

Authors:  Zhonghan Li; Tariq M Rana
Journal:  Nat Rev Drug Discov       Date:  2014-07-11       Impact factor: 84.694

3.  Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency.

Authors:  Mary G Prieve; Pierrot Harvie; Sean D Monahan; Debashish Roy; Allen G Li; Teri L Blevins; Amber E Paschal; Matt Waldheim; Eric C Bell; Anna Galperin; Jean-Rene Ella-Menye; Michael E Houston
Journal:  Mol Ther       Date:  2018-01-04       Impact factor: 11.454

Review 4.  Targeting pattern recognition receptors in cancer immunotherapy.

Authors:  Nadège Goutagny; Yann Estornes; Uzma Hasan; Serge Lebecque; Christophe Caux
Journal:  Target Oncol       Date:  2012-03-08       Impact factor: 4.493

5.  Promiscuous 8-alkoxyadenosines in the guide strand of an siRNA: modulation of silencing efficacy and off-pathway protein binding.

Authors:  Uday Ghanty; Erik Fostvedt; Rachel Valenzuela; Peter A Beal; Cynthia J Burrows
Journal:  J Am Chem Soc       Date:  2012-10-11       Impact factor: 15.419

6.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

7.  Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Authors:  Priscilla N Kelly; Donna L Romero; Yibin Yang; Arthur L Shaffer; Divya Chaudhary; Shaughnessy Robinson; Wenyan Miao; Lixin Rui; William F Westlin; Rosana Kapeller; Louis M Staudt
Journal:  J Exp Med       Date:  2015-11-30       Impact factor: 14.307

8.  Prediction of Immunomodulatory potential of an RNA sequence for designing non-toxic siRNAs and RNA-based vaccine adjuvants.

Authors:  Kumardeep Chaudhary; Gandharva Nagpal; Sandeep Kumar Dhanda; Gajendra P S Raghava
Journal:  Sci Rep       Date:  2016-02-10       Impact factor: 4.379

9.  Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Authors:  Shunsuke Wada; Satoshi Obika; Masa-Aki Shibata; Tsuyoshi Yamamoto; Moeka Nakatani; Tetsuji Yamaoka; Hidetaka Torigoe; Mariko Harada-Shiba
Journal:  Mol Ther Nucleic Acids       Date:  2012-09-18       Impact factor: 10.183

10.  Design of siRNA Therapeutics from the Molecular Scale.

Authors:  Phillip Angart; Daniel Vocelle; Christina Chan; S Patrick Walton
Journal:  Pharmaceuticals (Basel)       Date:  2013
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.